SCHEMBL3570709

SCHEMBL3570709

CN1CCN=C1c1ccc(NC(=O)C(NC(=O)Nc2ccc(Cl)cc2)c2cccs2)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
LMNA P02545 2/20 0.42
F10 P00742 5/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 3/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
EP300 Q09472 3/20 0.36
TSHR P16473 1/20 0.36
USP2 O75604 1/20 0.36
MAPK1 P28482 1/20 0.36
FPR2 P25090 1/20 0.36
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3569482 0.91 RAB9A (0.42) HTTRAB9AL3MBTL1ALDH1A1MAPT
SCHEMBL3566849 0.91 HTT (0.41) HTTRAB9ALMNAF10SMN1; SMN2
SCHEMBL3573944 0.89 HTT (0.40) HTTNPC1RAB9AF10SMN1; SMN2
SCHEMBL3565027 0.85 EP300 (0.48) F10ALDH1A1MAPTEP300FPR2
SCHEMBL3564096 0.85 EP300 (0.48) F10ALDH1A1MAPTEP300FPR2
SCHEMBL3570136 0.85 EP300 (0.48) F10ALDH1A1MAPTEP300FPR2
SCHEMBL3569137 0.84 F10 (0.40) HTTLMNAF10MAPTMEN1
SCHEMBL3558912 0.83 F10 (0.45) F10L3MBTL1MAPTEP300FPR2
SCHEMBL3574004 0.83 ROCK2 (0.46) F10EP300
SCHEMBL3568353 0.83 F10 (0.44) NPC1RAB9AF10MAPTEP300

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US claimed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US claimed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-7678913-B2 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2010-03-16 US disclosed
US-20060160821-A1 Ureas as factor Xa inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2006-07-20 US disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed
WO-2006063113-A2 UREAS AS FACTOR XA INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160821-A1 Ureas as factor Xa inhibitors TFPI, F12, F11 HTT 2690/4885NPC1 1325/4885RAB9A 2958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.